Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S2G6T-1 in Symptomatic Inflammatory Interdigital Tinea Pedis
NCT02842021Phase 2Terminated
- Sponsor
- Sol-Gel Technologies
- Start
- Sep 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of econazole and mometasone furoate nasal spray in tinea pedis (4 arms), sponsored by Sol-Gel Technologies. Primary endpoints: Complete cure at Day 29 and Reduction in Tinea pedis Symptoms through treatment period at Day 8. Started Sep 2016; status: terminated.
02
Drugs
econazolemometasone furoate nasal spray
03
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT02842021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842021.